Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival

Journal of Clinical Pathology

Volumn 61, Issue 7, 2008, Pages 856-862

  Paredes, J ^a,b   Correia, A L ^a   Ribeiro, A S ^b   Milanezi, F ^a,b   Cameselle Teijeiro, J ^c   Schmitt, F C ^a,b,d  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL XERAL CÍES   (Spain)

^d University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CADHERIN; ESTROGEN RECEPTOR ALPHA; P CADHERIN; PROTEIN P120; UVOMORULIN; CATENIN; DELTA CATENIN; MEMBRANE PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CELLULAR DISTRIBUTION; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; HUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; SURVIVAL; TUMOR VOLUME; BREAST TUMOR; METABOLISM; MIDDLE AGED; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CADHERINS; CATENINS; CYTOPLASM; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 47049094012     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.052704     Document Type: Article

References (58)

1. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990;59:237-52.
2. Geiger B, Ayalon 0. Cadherins. Annu Rev Cell Biol 1992;8:307-32.
3. Shapiro L, Fannon AM, Kwong PD, et al. Structural basis of cell-cell adhesion by cadherins. Nature 1995;374:327-37.
4. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-21.
5. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol 1997;13:119-46.
6. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
7. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
8. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993;142:987-93.
9. Tan DS, Potts HW, Leong AC, et al. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J Pathol 1999;189:20-7.
10. Bene G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14:6107-15.
11. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996;13:1919-25.
12. Julian S, Puig I, Caretti E, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007;26:7445-56.
13. Peinado H, Olmeda D, Cano A. Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
14. Chua HL, Bhat-Nakshatri P, Clare SE, et al. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007;26:711-24.
15. Castro Alves C, Rosivatz E, Schott C, et al. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol 2007;211:507- 15.
16. Elloul S, Elstrand MB, Nesland JM, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005;103:1631-43.
17. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-8.
18. Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78.
19. Cheng CW, Wu PE, Yu JC, et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 2001;20:3814-23.
20. Aigner K, Dampier B, Descovich L, et al. The transcription factor ZEB1 (deltaEFI) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007;26:6979- 88.
21. Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007;67:2030-9.
22. Maretzky T, Reiss K, Ludwig A, et al. ADAM 10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005;102:9182- 7.
23. Peralta SA, Knudsen KA, Salazar H, et al. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999;86:1263-72.
24. Paredes J, Milanezi F, Viegas L, et al. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch 2002;440:16-21.
25. Paredes J, Stove C, Stove V, et al. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res 2004;64:8309-17.
26. Paredes J, Albergaria A, Oliveira JT, et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005;11:5869-77.
27. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 1995;72:506-12.
28. Zschiesche W, Schonborn I, Behrens J, et al. Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 1997;17:561-7.
29. Pierceall WE. Woodard AS, Morrow JS, et al. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene 1995;11:1319-26.
30. Yoshida B, Kimura N, Harada Y, et al. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001;18:513-20.
31. Bukholm IK, Nesland JM, Karesen R, et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998;185:262-6.
32. Bukholm IR, Nesland JM, Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours. Pathology 2006;38:403-7.
33. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002;40:536-46.
34. Park D, Karesen R, Axcrona U, et al. Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. APMIS 2007;115:52-65.
35. Sanio D, Perez-Mies B, Hardisson D, et al. Cytoplasmic localisation of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004;23:3272-83.
36. Shibata T, Kokubu A, Sekine S, et al. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol 2004;164:2269-78.
37. Dillon DA, D'Aquila T, Reynolds AB, et al. The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. Am J Pathol 1998;152:75-82.
38. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
39. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-701.
40. Tolwinski NS, Wieschaus E. A nuclear function for armadillo/beta-catenin. PLoS Biol 2004;4:486-93.
41. Roczniak-Ferguson A, Reynolds AB. Regulation of p120-catenin nucleocytoplasmic shuttling activity. J Cell Sci 2003;116:4201-12.
42. Daniel JM. Dancing in and out of the nucleus: p12ctn and the transcription factor Kaiso. Biochim Biophys Acta 2007;1773:59-68.
43. Park Jl, Ji H, Jun S, et al. Frodo links Dishevelled to the p120-catenin/Kaiso pathway: distinct catenin subfamilies promote Wnt signals. Dev Cell 2006;11:683-95.
44. Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the Ecadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol 2007;20:130-8.
45. Kuroda H, Tamaru J, Takeuchi I, et al. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch 2006;448:500-5.
46. de Leeuw WJF, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997;183:404-11.
47. Moll B, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993;143:1731-42.
48. Parades J, Milanezi F, Reis-Filho JS, et al. Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? Pathol Res Pract 2002;198:795-801.
49. Sommers CL, Gelmann EP, Kemler R, et al. Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cells. Cancer Res 1994;54:3544-52.
50. Gillett CE, Miles DW, Ryder K. et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 2001;193:433- 41.
51. Taniuchi K, Nakagawa H, Hosokawa M, et al. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 2005;65:3092-9.
52. Anastasiadis PZ. p120-ctn: a nexus for contextual signaling via Rho GTPases. Biochim Biophys Acta 2007;1773:34-46.
53. Lochter A, Galosy S, Muschler J, et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861- 72.
54. Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/ stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46.
55. Parades J, Correia AL, Ribeiro AS, et al. P-cadherin expression in breast cancer: a review. Breast Cancer Res 2007,9:214.
56. Parades J, Lopes N, Milanezi F, et al. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 2007;450:73-80.
57. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688-94.
58. Ames JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11:4003-11.